Elamipretide confirmatory trial appears after accelerated approval
Why the 4TAZPower trial matters for Forzinity's narrow Barth syndrome approval.
By the PeptideFactSheets Editorial Team. Use the source links to verify status, evidence, risks, and unknowns; our editorial policyexplains the boundaries. Clinician review appears only when a named reviewer is shown.
The milestone
ClinicalTrials.gov lists 4TAZPower, a Phase 3b/4 randomized, double-blind, placebo-controlled study in people with genetically confirmed Barth syndrome.
The registry describes the trial as a post-marketing confirmatory study for elamipretide after Forzinity's accelerated FDA approval. The study record does not show public results.
Why it matters
- Forzinity's FDA approval was accelerated and narrow: it covers improving muscle strength in adults and pediatric patients with Barth syndrome who weigh at least 30 kilograms.
- Accelerated approval can rest on an endpoint considered reasonably likely to predict clinical benefit. The FDA announcement and label both state that continued approval may depend on confirmatory evidence.
- A registered confirmatory trial helps readers distinguish the approved intermediate-endpoint claim from broader mitochondrial, fatigue, performance, or healthy-aging claims that remain unproven.
What it means for readers
- The elamipretide fact sheet can now point to a specific confirmatory trial record instead of referring only generally to future confirmatory research.
- Nothing changed about the approved use: Forzinity remains approved only for the labeled Barth syndrome population, not for general mitochondrial support or athletic performance.
- The trial registration is not a result. It should not be read as proof that patient-centered benefit has been verified.
What remains uncertain?
- Whether the confirmatory trial will start, complete, and produce public results
- Whether functional outcomes will verify a patient-centered clinical benefit
- How the benefit-risk profile will look with more participants and longer follow-up
- Whether any other mitochondrial-disease research will support separate indications
Related fact sheets
Source links
- 1clinical trialsClinicalTrials.gov: 4TAZPower
Registered post-marketing confirmatory trial for elamipretide in genetically confirmed Barth syndrome.
- 2fdaFDA prescribing information: Forzinity
Official label describing the approved use, accelerated-approval basis, and confirmation requirement.
- 3fdaFDA accelerated approval announcement
FDA announcement describing the approval and post-approval trial requirement.